(Q36289427)

English

Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

1 reference

Europe PubMed Central

Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

author name string

David B Hughes

1

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Mark L Britton

2

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

language of work or name

0 references

publication date

1 November 2005

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

1602-1620

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Clinical practice. Nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Diabetic renal disease: from recent studies to improved clinical practice

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Treatment of the patient with diabetes mellitus and risk of nephropathy: what do we know, and what do we need to learn?

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Albuminuria and vascular damage--the vicious twins

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Microalbuminuria as a predictor of clinical diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato Study

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Anti-proteinuric effects of combination therapy with enalapril and losartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Preventing microalbuminuria in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.11.1602

21 January 2018

Identifiers

10.1592/PHCO.2005.25.11.1602

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36289427&oldid=2055582330"